Centiva Capital’s Halozyme HALO Stock Holding History

Centiva Capital’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-11,700	Closed	-$422K	–	1851
2023 Q2	$422K	Buy	+11,700	New	+$399K	0.01%	904

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Centiva Capital's HALO Position: Q3 2025 in Review

Centiva Capital sold out of Halozyme (HALO) in Q3 2025, closing a stake of 8,369 shares — an estimated $435K sold.

Centiva Capital first reported a position in HALO in Q3 2019 and held it in 8 quarters. The position peaked at $643K in Q4 2024. 602 funds tracked by Wall St. Rank hold HALO as of Q3 2025.

Centiva Capital reported no remaining Halozyme position as of Q3 2025 after selling out during the quarter.
Centiva Capital sold 8,369 Halozyme shares in Q3 2025, an estimated $435K.
Centiva Capital first reported a position in Halozyme in Q3 2019 and held it in 8 quarters.
Centiva Capital's Halozyme position peaked at $643K in Q4 2024.
602 funds tracked by Wall St. Rank held Halozyme as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.